The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

AG-K-15241     2-(4,8-dimethylnona-3,7- dienyl)-6-methyl...

Synonyms: CTK8A1948, AC1L1J4B
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of D01803


Psychiatry related information on D01803


High impact information on D01803


Chemical compound and disease context of D01803


Biological context of D01803


Anatomical context of D01803

  • All these results suggest that plaunotol increases the PG levels in gastric mucosa by stimulating the PG biosynthesis, particularly the cellular phospholipase activity [16].
  • We investigated the role of endogenous prostaglandins in the inhibitory effect of exogenous secretin and the antiulcer agent plaunotol on gastric acid secretion in the rat [17].
  • These results suggest that the bactericidal effect of plaunotol against H. pylori is due to the interaction between this compound and the bacterial cell membrane [1].
  • Interactions of plaunotol with bacterial membranes [3].
  • We have investigated a potential anti-angiogenic effect of plaunotol, an extract from the leaves of Plau-noi, in an angiogenesis model consisting of human umbilical vein endothelial cells (HUVECs) [18].

Associations of D01803 with other chemical compounds


Gene context of D01803

  • Plaunotol and its main metabolite had no effect on PG cyclooxygenase activity [16].
  • We investigated the mechanism of plaunotol-mediated COX-2 induction in rat gastric epithelial (RGM1) cells [13].
  • On the other hand, plaunotol, an acyclic diterpene alcohol, has been reported to inhibit gastrin release by stimulating endogenous secretion release [10].
  • The MIC of plaunotol for 50 and 90% of the MSSA and MRSA were assessed by the MD method, as 16 microg/ml and > or = 1,024 microg/ml, respectively [20].
  • The results indicate that endogenous prostaglandins play a significant role in the inhibitory action of exogenous and plaunotol-released endogenous secretin in the rat [17].

Analytical, diagnostic and therapeutic context of D01803


  1. Bactericidal effect of plaunotol, a cytoprotective antiulcer agent, against Helicobacter pylori. Koga, T., Kawada, H., Utsui, Y., Domon, H., Ishii, C., Yasuda, H. J. Antimicrob. Chemother. (1996) [Pubmed]
  2. In-vitro and in-vivo antibacterial activity of plaunotol, a cytoprotective antiulcer agent, against Helicobacter pylori. Koga, T., Kawada, H., Utsui, Y., Domon, H., Ishii, C., Yasuda, H. J. Antimicrob. Chemother. (1996) [Pubmed]
  3. Interactions of plaunotol with bacterial membranes. Koga, T., Watanabe, H., Kawada, H., Takahashi, K., Utsui, Y., Domon, H., Ishii, C., Narita, T., Yasuda, H. J. Antimicrob. Chemother. (1998) [Pubmed]
  4. Combination therapy with mucosal protective agent for the eradication of Helicobacter pylori. Fukuda, Y., Yamamoto, I., Okui, M., Tonokatsu, Y., Tamura, K., Shimoyama, T. European journal of gastroenterology & hepatology. (1995) [Pubmed]
  5. Eradication of Helicobacter pylori with lansoprazole, amoxicillin, and plaunotol in duodenal ulcer patients. Shirai, T., Takagi, A., Kurumada, T., Ohta, U., Kobayashi, H., Harasawa, S., Miwa, T. J. Clin. Gastroenterol. (1995) [Pubmed]
  6. Effect of plaunotol in combination with clarithromycin or amoxicillin on Helicobacter pylori in vitro and in vivo. Koga, T., Inoue, H., Ishii, C., Okazaki, Y., Domon, H., Utsui, Y. J. Antimicrob. Chemother. (2002) [Pubmed]
  7. Plaunotol prevents indomethacin-induced gastric mucosal injury in rats by inhibiting neutrophil activation. Murakami, K., Okajima, K., Harada, N., Isobe, H., Liu, W., Johno, M., Okabe, H. Aliment. Pharmacol. Ther. (1999) [Pubmed]
  8. Eradication of Helicobacter pylori in patients with end-stage renal disease under dialysis treatment. Tamura, H., Tokushima, H., Murakawa, M., Matsumura, O., Itoyama, S., Sekine, S., Hirose, H., Mitarai, T., Isoda, K. Am. J. Kidney Dis. (1997) [Pubmed]
  9. Effect of plaunotol on gastric injury induced by ischaemia-reperfusion in rats. Wada, K., Kamisaki, Y., Nakamoto, K., Kishimoto, Y., Ashida, K., Itoh, T. J. Pharm. Pharmacol. (1997) [Pubmed]
  10. Effect of plaunotol on hypergastrinemia induced by long-term omeprazole administration in humans. Kaneko, H., Mitsuma, T., Nagai, H., Harada, M., Kotera, H., Furusawa, A., Morise, K. Dig. Dis. Sci. (1995) [Pubmed]
  11. A highly stereoselective synthesis of plaunotol and its thiourea derivatives as potent antibacterial agents against Helicobacter pylori. Kogen, H., Tago, K., Arai, M., Minami, E., Masuda, K., Akiyama, T. Bioorg. Med. Chem. Lett. (1999) [Pubmed]
  12. Evaluation of a new bismuth-free triple therapy in nude mice and humans. Karita, M., Tsuda, M., Okita, K., Sugiyama, T., Nakazawa, T. European journal of gastroenterology & hepatology. (1995) [Pubmed]
  13. (2E,6Z,10E)-7-hydroxymethyl-3,11,15-trimethyl-2,6,10,14-hexadecatetraen-1-ol (Plaunotol) increases cyclooxygenase-2 expression via nuclear factor kappaB and cyclic AMP response element in rat gastric epithelial cells. Fu, H., Yabe, Y., Asahi, K., Hayashi, Y., Murata, H., Eguchi, H., Tsujii, M., Tsuji, S., Kawano, S. Eur. J. Pharmacol. (2005) [Pubmed]
  14. Plaunotol suppresses interleukin-8 secretion induced by Helicobacter pylori: therapeutic effect of plaunotol on H. pylori infection. Takagi, A., Koga, Y., Aiba, Y., Kabir, A.M., Watanabe, S., Ohta-Tada, U., Osaki, T., Kamiya, S., Miwa, T. J. Gastroenterol. Hepatol. (2000) [Pubmed]
  15. Effect of plaunotol on bacterial translocation in the rat small intestine. Sakai, T., Yamashita, Y., Maekawa, T., Shirakusa, T., Okabe, N. International surgery. (2000) [Pubmed]
  16. Stimulation of prostaglandin production by (2E,6Z,10E)-7-hydroxymethyl-3,11,15-trimethyl-2,6,10,14-++ +hexadecatetrae n-1-ol (plaunotol), a new anti-ulcer drug, in vitro and in vivo. Ushiyama, S., Matsuda, K., Asai, F., Yamazaki, M. Biochem. Pharmacol. (1987) [Pubmed]
  17. Role of endogenous prostaglandins in secretin- and plaunotol-induced inhibition of gastric acid secretion in the rat. Shiratori, K., Watanabe, S., Takeuchi, T. Am. J. Gastroenterol. (1993) [Pubmed]
  18. Anti-angiogenic properties of plaunotol. Kawai, K., Tsuno, N.H., Kitayama, J., Okaji, Y., Yazawa, K., Asakage, M., Yamashita, H., Watanabe, T., Takahashi, K., Nagawa, H. Anticancer Drugs (2005) [Pubmed]
  19. Effect of plaunotol on release of plasma secretin and pancreatic exocrine secretion in humans. Shiratori, K., Watanabe, S., Takeuchi, T., Chang, J.H., Moriyoshi, Y. Pancreas (1989) [Pubmed]
  20. Comparison of the effects in vitro of tea tree oil and plaunotol on methicillin-susceptible and methicillin-resistant strains of Staphylococcus aureus. Hada, T., Furuse, S., Matsumoto, Y., Hamashima, H., Masuda, K., Shiojima, K., Arai, T., Sasatsu, M. Microbios (2001) [Pubmed]
  21. The antibacterial activity of plaunotol against Staphylococcus aureus isolated from the skin of patients with atopic dermatitis. Matsumoto, Y., Hamashima, H., Masuda, K., Shiojima, K., Sasatsu, M., Arai, T. Microbios (1998) [Pubmed]
WikiGenes - Universities